The Latest Breaking News from Vertex Pharmaceuticals

The FDA cleared Vertex to restart testing a diabetes treatment, and VRTX stock jumped to a fresh high Wednesday.

Vertex Pharmaceuticals's (NASDAQ:VRTX) short percent of float has fallen 11.26% since its last report. The company recently reported that it has 3.42 million shares sold short, which is 1.34% of all regular shares that are available for trading.

The market is in a tough place with stubbornly high inflation, a hawkish Fed, and a slowing economy. These conditions are tough for most stocks, but pharmaceuticals are an exception. One of the top companies in the space is Vertex Pharmaceuticals (VRTX). Read on to find out why it's our…

Biotech stock United Therapeutics joins peers Vertex and Harmony Biosciences on the Breakout Stocks Index as it reenters a buy zone.

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 8.19% on an annualized basis producing an average annual return of 15.06%. Currently, Vertex Pharmaceuticals has a market capitalization of $67.67 billion.

Over the past 3 months, 8 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

The Dow Jones Industrial Average dived Friday on a hot inflation report in the wake of Thursday's stock market sell-off. DocuSign plunged on earnings.

The Dow Jones Industrial Average fell Thursday after unemployment data. Tesla stock raced higher on news that May sales in China rebounded.

Vertex Pharmaceuticals (NASDAQ: VRTX) received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its drug candidate inaxaplin (VX-147) for the treatment of patients with APOL1-mediated focal segmental glomerulosclerosis (FSGS).

The Dow Jones Industrial Average fell Wednesday, as Treasury yields jumped. Top stocks to buy and watch include cosmetics leader Ulta Beauty.

The market rally had a bullish reaction to the new Target warning. China EV giant BYD will supply batteries to Tesla.